[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Smallpox (Infectious Disease) - Drugs in Development, 2021

March 2021 | 88 pages | ID: S4371CBEB8A9EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Smallpox (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Drugs in Development, 2021, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smallpox - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 2, 1, 6 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Smallpox - Overview
Smallpox - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Smallpox - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smallpox - Companies Involved in Therapeutics Development
AlphaVax Inc
Bavarian Nordic A/S
BioFactura Inc
Chimerix Inc
EpiVax Inc
HK inno.N Corp
Polyrizon Ltd
SIGA Technologies Inc
Tonix Pharmaceuticals Holding Corp
Viraze
Smallpox - Drug Profiles
brincidofovir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-40011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Smallpox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIOCH-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox and monkeypox [ankara] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
smallpox vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tecovirimat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-1200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNX-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIR-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Smallpox - Dormant Projects
Smallpox - Discontinued Products
Smallpox - Product Development Milestones
Featured News & Press Releases
Jan 13, 2021: SIGA Announces Public Health Agency of Canada contract award to purchase up to approximately $33 million of oral TPOXX
Jan 05, 2021: Bavarian Nordic to supply smallpox vaccines to three European countries
Dec 16, 2020: Bavarian Nordic secures second part of Smallpox Vaccine order from the U.S. Government
Dec 07, 2020: Chimerix announces FDA acceptance of New Drug Application for brincidofovir as a medical countermeasure for smallpox
Dec 04, 2020: Vaccine genome researchers report 99.7% colinear identity between a U.S. civil war era smallpox vaccine and horsepox virus
Nov 12, 2020: SIGA Technologies Chief Scientific Officer to participate at NCT Asia Virtual Conference
Oct 08, 2020: SIGA announces Public Health Agency of Canada intent to purchase up to 33,300 courses of Oral TPOXX
Aug 24, 2020: Bavarian Nordic announces positive topline results from Phase 3 Clinical Study of Freeze-dried Smallpox Vaccine
Jul 30, 2020: SIGA announces marketing authorization filing for oral tecovirimat with the European Medicines Agency for multiple indications
Jun 25, 2020: SIGA announces deliveries of oral TPOXX to HHS valued at approximately $32 million
Jun 15, 2020: SIGA Technologies announces Department of Defense increases funding to develop Post-Exposure Prophylactic indication for TPOXX
Jun 01, 2020: SIGA Technologies announces first international delivery of oral TPOXX®
Apr 30, 2020: Bavarian Nordic announces a new order for JYNNEOS Smallpox Vaccine from the U.S. Government potentially worth USD 200 million
Apr 29, 2020: SIGA announces BARDA exercise of contract options valued at $101.3 million for the procurement of oral TPOXX
Apr 28, 2020: Chimerix receives FDA Clearance for rolling submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Smallpox, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Smallpox - Pipeline by AlphaVax Inc, 2021
Smallpox - Pipeline by Bavarian Nordic A/S, 2021
Smallpox - Pipeline by BioFactura Inc, 2021
Smallpox - Pipeline by Chimerix Inc, 2021
Smallpox - Pipeline by EpiVax Inc, 2021
Smallpox - Pipeline by HK inno.N Corp, 2021
Smallpox - Pipeline by Polyrizon Ltd, 2021
Smallpox - Pipeline by SIGA Technologies Inc, 2021
Smallpox - Pipeline by Tonix Pharmaceuticals Holding Corp, 2021
Smallpox - Pipeline by Viraze, 2021
Smallpox - Dormant Projects, 2021
Smallpox - Dormant Projects, 2021 (Contd..1)
Smallpox - Discontinued Products, 2021

LIST OF FIGURES

Number of Products under Development for Smallpox, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


More Publications